







## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Bissell et al.

Serial No.:

09/652,493

Group No.:

1642

Filed:

August 31, 2000

Examiner:

Davis

FEB 2 2 2002 TECH CENTER 1600/2900

Entitled:

DESIGN OF NOVEL DRUG SCREENS BASED ON THE NEWLY

FOUND ROLE OF DYSTROGLYCAN PROFEOLYSIS IN TUMOR

**CELL GROWTH** 

## RESPONSE TO OFFICE ACTION MAILED 10/02/01

Assistant Commissioner for Patents Washington, D.C. 20231

CERTIFICATE OF FACSIMILE TRANSMISSION UNDER 37 C.F.R. § 1.8(a)(1)(i)(B)

I hereby certify that this correspondence (along with any referred to as being attached or enclosed) is, on the date shown below, being facsimile transmitted to the United States Patent and Trademark Office, January 3, 2002

Fax No (703) 308-6410 on

By:

Examiner:

The following communication is responsive to the Office Action mailed October

2, 2001. Applicants request reconsideration of the above application in view of the following amendments and remarks. Please amend the application as follows:

## In the Specification:

Please replace the paragraph beginning at page 9, with the following rewritten paragraph:

CCPY OF PAPERS ORIGINALLY FILED \*\*\*\*\*\*\*\* DATE JAN-03-2002 \*\*\*\*\* TIME 17:16 \*\*\* P.01 MEMILRY TRANSMISSION FILE NO. = 071 NO. COM ABBR/NTWK STATION NAME/ PAGES PRG. NO. PROGRAM NAME TELEPHONE NO. 001 ΩK 917033084315 016/016 RECEIVED 

TECH CENTER 1600/2900

FAX

Ernest Orlando Lawrence Berkeley National Laboratory Office of the Laboratory Counsel Patent Department MS 90-1121

DATE: 01/03/02 TO: Examiner Natalie A. Davis, Ph.D. FAX: (703) 308-4315 LOCATION: In the United States Patent and Trademark Office TEL: (703) 308-6410 FROM: David J. Aston FAX: (510) 486-7896 LOCATION: Building 90, Mail Stop 90-B TEL: (510) 495-2839

## TOTAL NUMBER OF PAGES (INCLUDING THIS ONE): 16

This facsimile contains confidential information which may also be privileged. Unless you are the addressee (or authorized to receive for the addressee) you may not copy, use or distribute it. If you have received it in error, please inform the LBNL Patent Department Immediately by telephone or lacsimile and return it promptly by mail. If the box below is checked, this communication is subject to attorney-client and/or attorney work product privileges PRIVILEGED IF

Dear Examiner Davis,

Please find the attached Response to the Office Action, mailed October 2, 2001, for Application Number 09/652,493, entitled "DESIGN OF NOVEL DRUG SCREENS BASED ON THE NEWLY FOUND ROLE OF DYSTROGLYCAN PROTEOLYSIS IN TUMOR CELL GROWTH," and a Petition for an Extension of Time. A confirmation copy of this response will follow by

If you encounter any problems with this transmission, please call me at (510) 495-2839. Thank you.

Very truly yours,

David J. Aston, Esq.

Reg. No. 28,051

CONFIRMATION COPY

Ernest Orlando Lawrence Berkeley National Laboratory One Cyclotron Road | Berkeley, California 94720